Patterns of Efavirenz use as First-Line Antiretroviral Therapy in the United States: 1999–2015

Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. (Updated 8 April 2015. Accessed 11 October 2016.) Available from https://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL003400.pdf.

Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents: Department of Health and Human Services and the Henry J. Kaiser Family Foundation. (Updated 5 May 1999. Accessed 11 November 2016.) Available from https://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL05051999011.pdf.

Raff F. , Pozniak A.L. , Wainberg M.A. Has the time come to abandon efavirenz for first-line antiretroviral therapy? J Antimicrob Chemother 2014; 69: 1742–1747.

World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach. 2010. (Accessed 11 November 2016.) Available from http://www.who.int/hiv/pub/arv/adult2010/en.

Kryst J. , Kawalec P. , Pilc A. Efavirenz-based regimens in antiretroviral-naive HIV-infected patients: a systematic review and meta-analysis of randomized controlled trials. PLoS One 2015; 10: e0124279.

Coovadia A. , Abrams E.J. , Strehlau R. Efavirenz-based antiretroviral therapy among nevirapine-exposed HIV-infected children in South Africa: a randomized clinical trial. JAMA 2015; 314: 1808–1817.

Iwuji C.C. , Orne-Gliemann J. , Larmarange J. Universal test and treat and the HIV epidemic in rural South Africa: a Phase 4, open-label, community cluster randomised trial. Lancet HIV 2017; doi: 10.1016/S2352-3018(17)30205-9.

Masimirembwa C. , Dandara C. , Leutscher P.D. Rolling out efavirenz for HIV precision medicine in Africa: are we ready for pharmacovigilance and tackling neuropsychiatric adverse effects? OMICS 2016; 20: 575–580.

Sonderup M.W. , Maughan D. , Gogela N. Identification of a novel and severe pattern of efavirenz drug-induced liver injury in South Africa. AIDS 2016; 30: 1483–1485.

Kenedi C.A. , Goforth H.W. A systematic review of the psychiatric side-effects of efavirenz. AIDS Behav 2011; 15: 1803–1818.

Sustiva (efavirenz). Package insert 2013. Bristol–Myers Squibb Princeton, NJ, USA.

Mollan K.R. , Smurzynski M. , Eron J.J. Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data. Ann Intern Med 2014; 161: 1–10.

Arenas-Pinto A. , Grund B. , Sharma S. Increased risk of suicidal behaviour with use of efavirenz: results from the START Trial. AIDS. 18–22 July 2016, Durban, South Africa. Abstract THAB0202.

Napoli A.A. , Wood J.J. , Coumbis J.J. , Soitkar A.M. , Seekins D.W. , Tilson H.H. No evident association between efavirenz use and suicidality was identified from a disproportionality analysis using the FAERS database. J Int AIDS Soc 2014; 17: 19214.

Nkhoma E.T. , Coumbis J. , Farr A.M. No evidence of an association between efavirenz exposure and suicidality among HIV patients initiating antiretroviral therapy in a retrospective cohort study of real world data. Medicine 2016; 95: e2480.

Smith C. , Ryom L. , Monforte A. Lack of association between use of efavirenz and death from suicide: evidence from the D:A:D study. J Int AIDS Soc 2014; 17 Suppl 2: 19512.

Kitahata M.M. , Rodriguez B. , Haubrich R. Cohort profile: the Centers for AIDS research network of integrated clinical systems. Int J Epidemiol 2008; 37: 948–955.

Department of Health and Human Services, Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. (Updated 2016. Accessed 16 October 2017.) Available from http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.

Akiskal H.S. , Benazzi F. Psychopathologic correlates of suicidal ideation in major depressive outpatients: is it all due to unrecognized (bipolar) depressive mixed states? Psychopathology 2005; 38: 273–280.

Ashrafoun L. , Pigeon W.R. , Conner K.R. , Leong S.H. , Oslin D.W. Prevalence and correlates of suicidal ideation and suicide attempts among veterans in primary care referred for a mental health evaluation. J Affect Disord 2016; 189: 344–350.

Kroenke K. , Spitzer R.L. , Williams J.B. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001; 16: 606–613.

Spitzer R.L. , Kroenke K. , Williams J.B. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA. 1999; 282: 1737–1744.

Babor T.F. , Higgins-Biddle J.C. , Saunders J.B. , Monteiro M.G. AUDIT, The Alcohol Use Disorders Identification Test. Guidelines for Use in Primary Care. Geneva, Switzerland: World Health Organization, Dependence DoMHaS; 2001. (Accessed 16 October 2017.) Available from http://apps.who.int/iris/bitstream/handle/10665/67205/WHO_MSD_MSB_01.6a.pdf;jsessionid=4C151A61DCEDB155672A614E64566BF4?sequence=1.

WHO ASSIST Working Group. The alcohol, smoking and substance involvement screening test (ASSIST): development, reliability and feasibility. Addiction 2002; 97: 1183–1194.

Humeniuk R. , Ali R. , Babor T.F. Validation of the alcohol, smoking and substance involvement screening test (ASSIST). Addiction 2008; 103: 1039–1047.

Chesney M.A. , Ickovics J.R. , Chambers D.B. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care 2000; 12: 255–266.

Amico K.R. , Fisher W.A. , Cornman D.H. Visual analog scale of ART adherence: association with 3-day self-report and adherence barriers. J Acquir Immune Defic Syndr 2006; 42: 455–459.

Vrouenraets S.M. , Wit F.W. , van Tongeren J. , Lange J.M. Efavirenz: a review. Expert Opin Pharmacother 2007; 8: 851–871.

Bengtson A.M. , Pence B.W. , Crane H.M. Disparities in depressive symptoms and antidepressant treatment by gender and race/ethnicity among people living with HIV in the United States. PLoS One 2016; 11: e0160738.

Chersich M.F. , Urban M.F. , Venter F.W. Efavirenz use during pregnancy and for women of child-bearing potential. AIDS Res Ther 2006; 3: 11.

Mirochnick M. , Best B.M. , Clarke D.F. Antiretroviral pharmacology: special issues regarding pregnant women and neonates. Clin Perinatol 2010; 37: 907–927.

De Santis M. , Carducci B. , De Santis L. , Cavaliere A.F. , Straface G. Periconceptional exposure to efavirenz and neural tube defects. Arch Intern Med 2002; 162: 355.

Eaton E.F. , Tamhane A.R. , Burkholder G.A. , Willig J.H. , Saag M.S. , Mugavero M.J. Unanticipated effects of new drug availability on antiretroviral durability: implications for comparative effectiveness research. Open Forum Infect Dis 2016; 3: ofw109.

FDA notifications. Accelerated approval for raltegravir tablets. Aids Alert 2007; 22: 143–144.

Juethner S.N. , Seyfried W. , Aberg J.A. Tolerance of efavirenz-induced central nervous system side effects in HIV-infected individuals with a history of substance abuse. HIV Clin Trials 2003; 4: 145–149.

Fumaz C.R. , Munoz-Moreno J.A. , Molto J. Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence. J Acquir Immune Defic Syndr 2005; 38: 560–565.

Steigbigel R.T. , Cooper D.A. , Kumar P.N. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008; 359: 339–354.

D'Abbraccio M. , Busto A. , De Marco M. , Figoni M. , Maddaloni A. , Abrescia N. Efficacy and tolerability of integrase inhibitors in antiretroviral-naive patients. AIDS Rev 2015; 17: 171–185.

Cotte L. , Ferry T. , Pugliese P. Effectiveness and tolerance of single tablet versus once daily multiple tablet regimens as first-line antiretroviral therapy - results from a large French multicenter cohort study. PLoS One 2017; 12: e0170661.

Fettiplace A. , Stainsby C. , Winston A. Psychiatric symptoms in patients receiving dolutegravir. J Acquir Immune Defic Syndr 2017; 74: 423–431.

Khelouf F. , Allemand J. , Mokhtari S. , Default A. Psychiatric disorders after starting dolutegravir: report of four cases. AIDS 2015; 29: 1723–1725.

Parant F. , Miailhes P. , Brunel F. , Gagnieu M.C. Dolutegravir-related neurological adverse events: a case report of successful management with therapeutic drug monitoring. Curr Drug Saf 2018; 13: 69–71.

Scheper H. , van Holten N. , Hovens J. , de Boer M. Severe depression as a neuropsychiatric side effect induced by dolutegravir. HIV Med 2018; 19: e58–e59.